Dr Aeron Hurt | Principal Global Medical Science Director, Influenza and COVID-19

Dr Aeron Hurt, Principal Global Medical Science Director, Influenza and COVID-19, Roche

Dr. Aeron Hurt is the Principal Global Medical Director, for both COVID-19 and Influenza at Roche, Basel, Switzerland. Aeron was previously Head of the Antiviral Susceptibility Analysis Surveillance Unit and Research group at the WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia. Aeron has had a career-long interest in antivirals and regularly acted as an external Temporary Advisor to the WHO. He has completed a number of short-term consultancies for the WHO, and national Governments related to influenza surveillance, epidemiology and laboratory analysis. Aeron has published over 180 peer-reviewed research and review papers in the field of influenza, COVID-19 and virology including articles in Science, Nature, New England Journal of Medicine, Nature Medicine and Lancet Infectious Diseases. Aeron completed a PhD in influenza virology at Monash University and is currently an Associate Professor with the University of Melbourne.


WVIC/WAC Day 3 - Dec 1 @ 10:00

Chair’s opening remarks

WVIC/WAC Day 3 - Dec 1 @ 11:10

The role of influenza antivirals–How can we reduce morbidity and mortality at the individual and population level?

last published: 01/Dec/22 17:25 GMT

back to speakers

For conference programme and speaking opportunities:
Lauren Sheppard


For sponsorship and exhibition opportunities:
Thomas Hall